ALT
2.67 USD
-3.33%
Today
-3.69%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 11:00 PM
Tue
4:30 PM ~ 11:00 PM
Wed
4:30 PM ~ 11:00 PM
Thu
4:30 PM ~ 11:00 PM
Fri
4:30 PM ~ 11:00 PM
Sat
Closed
Information
Name
Altimmune Inc Leveraged
Currency
USD
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0183%
Overnight Fees Sell
0.0016%
Market Cap
598.01M
Avg Daily Volume
2.66M
52 Week High
7.73 USD
52 Week Low
2.56 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01830% | $(0.183) |
| SELLS | 0.00160% | $0.016 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Top News
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
tradingview.com
1d ago
ALT and the Rise of Dual Agonists Targeting Liver Disease
tradingview.com
1d ago
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
tradingview.com
1d ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
